跳转至内容
Merck
CN
所有图片(1)

主要文件

528117

Sigma-Aldrich

PI 3-K抑制剂IX,PIK-90

The PI 3-K inhibitor IX, PIK-90, also referenced under CAS 677338-12-4, controls the biological activity of PI 3-K. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

PI 3-K抑制剂IX,PIK-90

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H17N5O3
分子量:
351.36
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

pale yellow

溶解性

DMSO: 0.5 mg/mL

运输

wet ice

储存温度

−20°C

SMILES字符串

[n]21[c](c3c(nc2NC(=O)c4cnccc4)c(c(cc3)OC)OC)=NCC1

InChI

1S/C18H17N5O3/c1-25-13-6-5-12-14(15(13)26-2)21-18(23-9-8-20-16(12)23)22-17(24)11-4-3-7-19-10-11/h3-7,10H,8-9H2,1-2H3,(H,21,22,24)

InChI key

ZJAVHOMVDCMAMF-UHFFFAOYSA-N

一般描述

一种具有细胞渗透性的咪唑喹唑啉化合物,可作为一种针对全部三类PI 3-K激酶(p110α,p110γ、PI 3-KC2α,p110δ,PI 3-KC2β,p110β和hsVPS34的IC50 分别为11,18、47、58、64、350和830 nM)以及几种PIKK(DNA-PK,ATM和mTORC1的IC50 分别为13、610和1050 nM)和PI 4-KIIIα(IC50 =830 nM)的强效、可逆的ATP竞争性抑制剂,同时对PI 4-KIIIβ和ATR的效价大大降低(分别为IC50 =3.1和15 µM),对PI 4-KIIα,PIPK(IC50 >100 µM)以及一组36种常用研究的蛋白激酶(在2.5 µM时为<15% inhibition at 10 µM). Effectively suppreses insulin-stimulated phosphorylations of Akt and rpS6 in 3T3-L1 adipocytes and L6 myotubes in a dose-dependent manner in vitro (by >90%)的活性很小或没有活性,并完全防止小鼠体内胰岛素诱导的血糖下降(10 mg/ml,i.p.)。

包装

用惰性气体包装

警告

毒性:标准处理(A)

制备说明

完全溶解可能需要轻微加热。

重悬

复溶后,等分并冷冻保存(-20°C)。贮备液在-20°C下可稳定保存至多3个月。

其他说明

Fan, Q.W., et al. 2007.Cancer Res.67, 7960.
Fan, Q.W., et al. 2006.Cancer Cell9, 341.
Knight, Z.A., et al. 2006.Cell125, 733.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lay Teng Ang et al.
Cell, 185(14), 2523-2541 (2022-06-24)
Stem cell research endeavors to generate specific subtypes of classically defined "cell types." Here, we generate >90% pure human artery or vein endothelial cells from pluripotent stem cells within 3-4 days. We specified artery cells by inhibiting vein-specifying signals and vice
Keishi Kishimoto et al.
Nature protocols, 17(11), 2699-2719 (2022-08-18)
Development of visceral organs such as the esophagus, lung, liver and stomach are coordinated by reciprocal signaling interactions between the endoderm and adjacent mesoderm cells in the fetal foregut. Although the recent successes in recapitulating developmental signaling in vitro has
Tomoka Takao et al.
STAR protocols, 3(4), 101786-101786 (2022-11-02)
Here, we present a protocol for the selective differentiation of human pluripotent stem cells mimicking human developmental processes into expandable PRRX1+ limb-bud mesenchymal (ExpLBM) cells. This approach enables expansion through serial passage while maintaining capacity for chondrogenic differentiation. For complete
Stephen J Gadomski et al.
iScience, 27(8), 110537-110537 (2024-08-28)
Stem cell therapies for degenerative cartilage disease are limited by an incomplete understanding of hyaline cartilage formation and maintenance. Human bone marrow stromal cells/skeletal stem cells (hBMSCs/SSCs) produce stable hyaline cartilage when attached to hyaluronic acid-coated fibrin microbeads (HyA-FMBs), yet
Alexandra K Eicher et al.
Cell stem cell, 29(1), 36-51 (2021-12-03)
Human organoid model systems lack important cell types that, in the embryo, are incorporated into organ tissues during development. We developed an organoid assembly approach starting with cells from the three primary germ layers-enteric neuroglial, mesenchymal, and epithelial precursors-that were

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门